The new acting commissioner of the Food and Drug Administration is facing pressure from the anti-abortion lobby after it emerged that Kyle Diamantas had previously been retained as corporate counsel for Planned Parenthood, despite strong support from the Trump administration and top leaders in the movement.
Diamantas, 38, was previously the director of the Human Foods Program at the FDA and was selected to work as acting commissioner after President Donald Trump’s first FDA commissioner, Marty Makary, abruptly resigned this week. Almost immediately after his appointment was announced, anti-abortion activists began to peer into his past, finding at least one eyebrow-raising instance in his professional career for what conservatives view as an unsavory former client.
